FDA approves Lumryz™ for treating narcolepsy in children aged 7+, expanding treatment options.

The FDA has approved Lumryz™ (sodium oxybate) extended-release oral suspension for treating cataplexy and excessive daytime sleepiness in children aged 7 and older with narcolepsy. Previously approved only for adults, this decision expands treatment options for pediatric patients, who make up 5% of the narcolepsy population receiving oxybate. Lumryz is a controlled substance due to risks of CNS depression and potential for misuse. Adverse reactions in children include nausea and dizziness.

October 17, 2024
11 Articles